Advanced in Thyroid Cancer

Dr. Jonas A. De Souza

Hematology Oncology
5200 S Ellis Ave, Apt 118n, 
Chicago, IL 
Advanced in Thyroid Cancer
5200 S Ellis Ave, Apt 118n, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jonas De Souza is a Hematologist Oncology provider in Chicago, Illinois. Dr. De Souza is rated as an Advanced provider by MediFind in the treatment of Thyroid Cancer. His top areas of expertise are Thyroid Cancer, Follicular Thyroid Cancer, Papillary Thyroid Cancer, and Glioma.

His clinical research consists of co-authoring 60 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles and participated in 2 clinical trials in the study of Thyroid Cancer.

Specialties
Hematology Oncology
Licenses
Internal Medicine in IL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

5200 S Ellis Ave, Apt 118n, Chicago, IL 60615

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers
Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers
Enrollment Status: Completed
Publish Date: March 28, 2025
Intervention Type: Drug, Other
Study Drugs: Sunitinib, Sunitinib Malate
Study Phase: Phase 2
Nab-Paclitaxel-based Re-induction Chemotherapy Followed by Response-stratified Chemoradiotherapy in Patients With Previously Treated Squamous Cell Carcinoma of the Head and Neck.
Nab-Paclitaxel-based Re-induction Chemotherapy Followed by Response-stratified Chemoradiotherapy in Patients With Previously Treated Squamous Cell Carcinoma of the Head and Neck.
Enrollment Status: Completed
Publish Date: July 31, 2024
Intervention Type: Procedure, Drug, Radiation, Other
Study Drugs: Carboplatin, Paclitaxel, 5-Fluorouracil, Hydroxyurea
Study Phase: Phase 1
Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) - a Phase 1/Randomized Phase 2 Study in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) - a Phase 1/Randomized Phase 2 Study in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
Enrollment Status: Completed
Publish Date: June 07, 2023
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, 5-Fluorouracil, Hydroxyurea, Paclitaxel, Veliparib
Study Phase: Phase 1/Phase 2
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Enrollment Status: Completed
Publish Date: July 15, 2021
Intervention Type: Other, Drug
Study Drugs: Cediranib, Cediranib Maleate, Lenalidomide
Study Phase: Phase 1/Phase 2
Randomized Placebo- Controlled Pilot Study of ZD6474 as a Chemopreventive Agent for Premalignant Lesions of the Head and Neck
Randomized Placebo- Controlled Pilot Study of ZD6474 as a Chemopreventive Agent for Premalignant Lesions of the Head and Neck
Enrollment Status: Completed
Publish Date: January 14, 2021
Intervention Type: Other, Procedure, Drug
Study Phase: Phase 2
A Pilot Feasibility Study of 99mTc EC DG SPECT/CT Imaging in the Treatment Response Evaluation in Patients With Locally Advanced Head and Neck Cancer
A Pilot Feasibility Study of 99mTc EC DG SPECT/CT Imaging in the Treatment Response Evaluation in Patients With Locally Advanced Head and Neck Cancer
Enrollment Status: Completed
Publish Date: May 08, 2020
Intervention Type: Drug
Study Phase: Early Phase 1
View 5 Less Clinical Trials

60 Total Publications

Palmitic acid alone or combined with stearic and oleic enhances ruminal fiber degradation and alters microbiome composition.
Palmitic acid alone or combined with stearic and oleic enhances ruminal fiber degradation and alters microbiome composition.
Journal: Frontiers in microbiology
Published: May 08, 2025
Similar Doctors
Distinguished in Thyroid Cancer
Dr. Ari J. Rosenberg
Hematology Oncology | Hematology | Oncology
Distinguished in Thyroid Cancer
Dr. Ari J. Rosenberg
Hematology Oncology | Hematology | Oncology

The University Of Chicago Medical Center

5841 S Maryland Ave, 
Chicago, IL 
 (0.8 miles away)
773-702-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ari Rosenberg is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Rosenberg is rated as a Distinguished provider by MediFind in the treatment of Thyroid Cancer. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Laryngeal Cancer, Adenoid Cystic Carcinoma, and Throat Cancer. Dr. Rosenberg is currently accepting new patients.

Advanced in Thyroid Cancer
Dr. Chih-yi '. Liao
Hematology Oncology | Hematology | Oncology
Advanced in Thyroid Cancer
Dr. Chih-yi '. Liao
Hematology Oncology | Hematology | Oncology

The University Of Chicago Medical Center

5841 S Maryland Ave, 
Chicago, IL 
 (0.8 miles away)
773-702-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Chih-yi Liao is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Liao is rated as a Distinguished provider by MediFind in the treatment of Thyroid Cancer. His top areas of expertise are Neuroendocrine Tumor, Cholangiocarcinoma (Bile Duct Cancer), Liver Cancer, Hepatectomy, and Gastrostomy. Dr. Liao is currently accepting new patients.

Advanced in Thyroid Cancer
Dr. Ira A. Oliff
Hematology Oncology | Hematology | Oncology
Advanced in Thyroid Cancer
Dr. Ira A. Oliff
Hematology Oncology | Hematology | Oncology
9711 Skokie Blvd, Ste A, 
Skokie, IL 
 (19.2 miles away)
847-568-9930
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ira Oliff is a Hematologist Oncology specialist and a Hematologist in Skokie, Illinois. Dr. Oliff is rated as a Distinguished provider by MediFind in the treatment of Thyroid Cancer. His top areas of expertise are Waldenstrom Macroglobulinemia, Lung Cancer, Colorectal Cancer, and Childhood Iron Deficiency Anemia. Dr. Oliff is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. De Souza's expertise for a condition
ConditionClose
      View All 24 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile